Atsumi Yamaguchi

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.

Kumiko Yoshimatsu, Atsumi Yamaguchi, Hiroshi Yoshino et al. · PubMed · 1997 · 181 citations

Medicine, Oncology, Pharmacology +14

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

Takayuki Nakagawa, Osamu Tohyama, Atsumi Yamaguchi et al. · Cancer Science · 2009 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Simple method of aequorin loading into platelets using dimethyl sulfoxide

Atsumi Yamaguchi, Hidenori Suzuki, Kenjiro Tanoue et al. · Thrombosis Research · 1986 · 68 citations

Medicine, Chemistry, Hematology +7

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

Masahiro Matsuki, Yusuke Adachi, Yoichi Ozawa et al. · Cancer Science · 2017 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17